NEW YORK (GenomeWeb News) – Agilent Technologies said yesterday that it is providing tools to Stemina Biomarker Discovery to accelerate its metabolomic research.
Agilent will provide Stemina with a 1290 Infinity UHPLC platform for the separation of stem cell metabolites, and a 6530 Q-TOF mass spec for the identification of metabolites. In addition, Agilent is providing Mass Profile Profession software for interpreting complex data generated from metabolomic research.
Based in Madison, Wis., Stemina uses metabolomic analysis of stem cells to discover biomarkers for use in drug screening and drug development.
In a statement, Gustavo Salem, vice president and general manager for Agilent's Biological Systems Division, said that metabolomics is a "major growth area" for the company, "and the innovative work being done at Stemina is the kind we like to support."